Prestige Consumer Healthcare (NYSE:PBH) Issues Quarterly Earnings Results

Posted by Geri Gentry on Nov 8th, 2026

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.06, FiscalAI reports. Prestige Consumer Healthcare had a return on equity of 11.28% and a net margin of 13.29%. The company had revenue of $336.31 million during the quarter, compared to the consensus estimate of $329.14 million. During the same quarter last year, the company earned $1.07 EPS. The company’s quarterly revenue was up 22.7% on a year-over-year basis.

Here are the key takeaways from Prestige Consumer Healthcare’s conference call:

Second-quarter revenue rose 22.7% to $336.3 million, reflecting the first full quarter of Breathe Right and LaCorium ownership; adjusted EPS increased about 6% to $1.13. Excluding acquisitions and foreign currency, revenue declined 1.6%, which management attributed partly to prior-quarter order timing.
Clear Eyes production volatility prompted a cut to the full-year outlook. Prestige now expects fiscal 2027 revenue of $1.28 billion–$1.29 billion and adjusted EPS of $4.48–$4.55; it expects less than $20 million in Clear Eyes sales for the year and said supply recovery will take time.
The company said its broader portfolio and recent acquisitions are performing well. First-half organic revenue grew about 1%, led by brands including Dramamine, TheraTears, Compound W, and Hydralyte; Breathe Right and LaCorium remain on track to contribute about $190 million in fiscal 2027 revenue.
Prestige reported mid-teens e-commerce consumption growth and market-share gains for many leading brands, as shoppers seek value through online and mass-market channels. Management plans to use free cash flow to reduce debt, while forecasting at least $265 million in adjusted free cash flow for the year.

Prestige Consumer Healthcare Price Performance

NYSE PBH traded down $1.29 on Friday, reaching $43.03. The company’s stock had a trading volume of 1,127,190 shares, compared to its average volume of 598,881. Prestige Consumer Healthcare has a 52 week low of $41.77 and a 52 week high of $71.07. The company has a current ratio of 2.92, a quick ratio of 1.99 and a debt-to-equity ratio of 1.08. The firm has a market cap of $2.04 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 1.35 and a beta of 0.30. The business has a 50-day moving average price of $48.17 and a 200 day moving average price of $53.77.

Analyst Ratings Changes

A number of analysts have recently issued reports on PBH shares. Weiss Ratings restated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 29th. Finally, Canaccord Genuity Group lowered their price target on shares of Prestige Consumer Healthcare from $72.00 to $70.00 and set a “buy” rating on the stock in a report on Friday. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $67.00.

Read Our Latest Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

Positive Sentiment: Fiscal Q2 adjusted earnings were $1.13 per share, topping the $1.07 consensus, while revenue of $336.31 million exceeded estimates of about $329 million and rose 22.7% year over year. Prestige Consumer Healthcare fiscal 2027 second-quarter results
Neutral Sentiment: Canaccord Genuity lowered its price target from $72 to $70 but maintained a Buy rating. The reduced target is a mild negative, though it still implies substantial upside from the cited share price. Canaccord Genuity Group stock recommendations
Negative Sentiment: A recent report highlights PBH’s stock drop, but the provided article details do not specify what is driving the decline. The weakness despite an earnings and revenue beat may indicate investors are weighing concerns not explained in the available coverage. Prestige Consumer Healthcare stock dropped: what is driving attention now?

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.